Wells Fargo’s Kyntra Bio KYNB Stock Holding History

Wells Fargo’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,188	Closed	-$1K	–	6438
2017 Q4	$1K	Buy	+1,188	New	+$1.49M	﹤0.01%	6246

Other funds holding KYNB

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Wells Fargo's KYNB Position: Q4 2024 in Review

Wells Fargo sold out of Kyntra Bio (KYNB) in Q4 2024, closing a stake of 400 shares — an estimated $3.99K sold.

Wells Fargo first reported a position in KYNB in Q1 2015 and held it in 39 quarters. The position peaked at $22.8M in Q1 2019. 68 funds tracked by Wall St. Rank hold KYNB as of Q4 2024.

Wells Fargo reported no remaining Kyntra Bio position as of Q4 2024 after selling out during the quarter.
Wells Fargo sold 400 Kyntra Bio shares in Q4 2024, an estimated $3.99K.
Wells Fargo first reported a position in Kyntra Bio in Q1 2015 and held it in 39 quarters.
Wells Fargo's Kyntra Bio position peaked at $22.8M in Q1 2019.
68 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2024.

Based on Wells Fargo's 13F filing for Q4 2024, filed 13 Feb 2025.